SecBot SecBot
10-Q/A ·Filed Nov 12, 2026

OSUR

ORASURE TECHNOLOGIES INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed4d 17h ago SEC0001116463-26-000066
Amended quarterly report (potential restatement)
Actionable Insight • Neutral

The amendment is purely administrative with no financial effect. Monitor the company's next filing for updates on the CT/NG regulatory submission plan and any impairment risk to the $17.0M IPR&D asset. The NowDiagnostics litigation resolution removes a legal overhang.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+1
Entry
$3.62
T+0 close · Nov 12, 2026 · via day close
Latest settled
0.00%
T+1 · $3.62
Vs SPY
+0.36%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $3.62entry
  2. T+1 · 4d ago 0.00%α +0.36% · $3.62
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

Executive Summary

OraSure filed an amended 10-Q/A solely to correct an administrative error in the XBRL Interactive Data Tables Exhibits that erroneously included references to a prospective transaction. The amendment does not affect the financial statements or narrative disclosures. The underlying quarterly report shows net revenue of $30.9M (up 14% YoY) but a net loss of $13.1M, with cash declining to $148.2M and a $22.5M non-cash benefit from reducing contingent consideration after withdrawing its CT/NG FDA submission.

Key Facts

  • Amendment corrects XBRL exhibits that erroneously referenced a prospective transaction; no financial statement changes.
  • Q3 2026 net revenue $30.9M, up 14% YoY from $27.1M.
  • Q3 2026 net loss $13.1M vs $13.7M loss in Q3 2025.
  • Cash and cash equivalents fell to $148.2M from $199.3M at Dec 31, 2025.
  • Recorded $22.5M non-cash benefit from reducing contingent consideration after withdrawing CT/NG FDA 510(k) submission in July 2026.
  • IPR&D intangible asset carrying value of $17.0M was 6% below fair value as of June 30, 2026; no impairment triggered in Q3.
  • Litigation with NowDiagnostics resolved on Oct 27, 2026 with permanent injunction and dismissal with prejudice.

Financial Impact

No financial impact from the amendment itself. The underlying report shows a $22.5M non-cash reduction in contingent consideration liability and a $17.0M IPR&D asset at risk if CT/NG regulatory path is further delayed.

contingent considerationIPR&D intangible assetnet loss

Risk Factors

  • CT/NG regulatory submission withdrawn; future submission timeline uncertain, creating risk of IPR&D impairment if further delays occur.
  • Cash burn continues with $34.7M used in operations over nine months; cash down to $148.2M with 55% held in Canadian subsidiary.
  • Accumulated deficit grew to $201.4M; full valuation allowance on U.S. and U.K. deferred tax assets remains.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
10-Q/A Filing (Primary)0001116463-26-000066
Document: osur-09302026xexx311.htm0001116463-26-000066
Document: osur-09302026xexx312.htm0001116463-26-000066
Document: osur-09302026xexx322.htm0001116463-26-000066
Document: osur-09302026xexx321.htm0001116463-26-000066
Document: 0001116463-26-000066-index-headers.html0001116463-26-000066
Document: 0001116463-26-000066-index.html0001116463-26-000066
Document: 0001116463-26-000066.txt0001116463-26-000066

Track record

20 reports on OSUR

Performance horizon

6 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +39.73% at T+60 after the Mar 13, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 10-Q/A Neutral 2/10 Viewing Entry $3.62 to $3.62 Now $3.60 −0.55% · 0.00% +0.36% vs SPY
  2. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $3.33 to $3.56 Now $3.60 +8.11% ▲ +6.91% +5.59% vs SPY
  3. Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $3.53 to $3.33 Now $3.60 +1.98% ▼ −5.67% −5.30% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $3.46 to $3.53 Now $3.60 +4.20% ▲ +2.17% +1.87% vs SPY
  5. Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $3.94 to $3.46 Now $3.60 −8.63% ▼ −12.31% −11.83% vs SPY
  6. Sep 17, 20268w ago SC 13D Bullish 6/10 Entry $3.56 to $3.69 Now $3.60 +1.12% ▲ +3.65% +2.10% vs SPY
  7. Jul 23, 202616w ago Court Ruling Neutral 3/10 Entry $3.97 to $3.96 Now $3.60 −9.32% ▼ −0.25% −0.27% vs SPY
  8. Jun 12, 202622w ago Institutional Cluster Mixed 4/10 Entry $4.18 to $4.17 Now $3.60 −13.88% ▼ −0.24% −2.00% vs SPY
  9. Jun 3, 202623w ago 8-K Neutral 3/10 Entry $4.17 to $4.04 Now $3.60 −13.67% ▼ −3.12% −0.52% vs SPY
  10. May 6, 202627w ago 8-K Bearish 6/10 Entry $3.13 to $3.06 Now $3.60 −15.02% ▲ +2.24% +3.07% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026